Skip to main content
OpenTrials
Completed

NCT Number: NCT00400426

DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer

Palliative radiotherapy for head and neck cancer is widely used but the effect and side effects are largely unknown. We will study the effect of short hypofractionated palliative radiotherapy (20 Gy in 4 fractions) on symptom intensity and -frequency as weel as side effects

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Department of Oncology

Aarhus, 8000 C, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Incurable primary or second primary head and neck cancer
  • Speaks and reads Danish
  • Capable of filling out questionnaires for at leas two months after radiotherapy
  • Age>=18 years
  • Expected survival> 3months

Treatment and study plan

Radiotherapy

Procedure

20 Gy in 4 fx

Primary outcomes

  1. Frequency and intensity of symptoms before and after radiotherapy (EORTC C30 and H&N35 questionnaires and CTC AE 3.0 toxicity scores)

    Time frame: 11 mths

Secondary outcomes

  1. Survival

    Time frame: 11 mths

  2. Side effects

    Time frame: 2 mths

  3. Other treatments

    Time frame: 11 mths

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Collaborators

  • Danish Head and Neck Cancer Group

Registry information

Important dates

Study start
2006
Primary completion
2012
Study completion
2012
First posted
Nov 16, 2006
Registry last updated
Jun 19, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.